How much revenue does Ipsen make?

Ipsen reported 3.93 billion EUR in revenue for fiscal year 2025, up 9.9% from 3.57 billion EUR in fiscal year 2024.

Where does Ipsen make most of its revenue?

United States: 33% of revenue by region in fiscal year 2025, followed by Europe (32%).

What companies are similar to Ipsen?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Valerio Therapeutics Société anonyme (ALVIO.PA), Transgene SA (TNG.PA), Oncodesign Precision Medicine Société anonyme (ALOPM.PA).

Ipsen S.a. (IPN.PA) Stock

About Ipsen S.a.

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic pro...

At a glance

Ipsen reported revenue of 3.93 billion EUR for fiscal year 2025, up 9.9% from fiscal year 2024, and net income of 443.50 million EUR. United States was its largest region in fiscal year 2025, with 33% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.